J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition.
Owen A. O'Connor,John Wright,Craig H. Moskowitz,Barbara MacGregor-Cortelli,David J. Straus,Andrew G. Evans,Jane N. Winter,Omer N. Koc,Nancy Horvath,Susan Blumel,Julie M. Vose,David P. Schenkein,Andrew D. Zelenetz +12 more
TL;DR: The data continue to support the activity of bortezomib in pts.
Journal ArticleDOI
Durable Responses After Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory (R/R) Aggressive Non-Hodgkin's Lymphoma (a-NHL): Results From An International Phase 2 Study (CC-5013-NHL-003).
Thomas E. Witzig,Julie M. Vose,Pier Luigi Zinzani,Craig B. Reeder,Rena Buckstein,Jonathan Polikoff,Pingshan Guo,Dennis Pietronigro,Annette Ervin-Haynes,Myron S. Czuczman +9 more
TL;DR: A large, international, confirmatory phase 2 study to assess the safety and efficacy of single-agent lenalidomide in patients with relapsed of refractory DLBCL or MCL supports earlier pilot-study results showing that lenalidumide has promising anti-tumor activity in aggressive B-cell NHL, with a predictable and treatable toxicity profile.
Journal ArticleDOI
Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results.
Steven M. Horwitz,Julie M. Vose,Ranjana H. Advani,Kamalesh Kumar Sankhala,Swaminathan Padmanabhan,Paul A. Hamlin,Andy I. Chen,Jasmine Zain,Steven M. Fruchtman,Owen A. O'Connor +9 more
TL;DR: A multi-center Phase 1/2a study to evaluate the maximum tolerated dose (MTD) and optimal Phase 2 dose and schedule for the combination of pralatrexate and gemcitabine in patients with relapsed or refractory lymphoma found this treatment combination is feasible with acceptable toxicity schedule.
Journal ArticleDOI
ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project.
Andrei R. Shustov,Andrei R. Shustov,Maria Elena Cabrera,Monica Civallero,Monica Bellei,Young Hyeh Ko,Martina Manni,Tetiana Skrypets,Steven M. Horwitz,Carmino Antonio De Souza,John Radford,Sabela Bobillo,Maria Virginia Prates,Andrés J.M. Ferreri,Carlos S. Chiattone,Michele Spina,Julie M. Vose,Annalisa Chiappella,Daniele Laszlo,Dario Marino,Caterina Stelitano,Massimo Federico +21 more
TL;DR: The T-Cell Project is a global prospective cohort study that consecutively enrolled patients newly diagnosed with peripheral T-cell lymphoma, registered through a centralized computer database between September 2006 and February 2018 as discussed by the authors.
Journal ArticleDOI
Superior outcomes associated with earlier use: Experience with tositumomab and iodine I 131 tositumomab in 1,177 patients (pts) with low-grade, follicular, and transformed non-Hodgkin’s lymphoma (NHL)
Stephanie A. Gregory,John P. Leonard,Julie M. Vose,Andrew D. Zelenetz,Sandra J. Horning,Susan J. Knox,T. A. Lister,John Radford,Oliver W. Press,Mark S. Kaminski +9 more
TL;DR: Efficacy is summarized by line of therapy, and all differences are highly statistically significant.